Akademik Veri Yönetim Sistemi
13th International Medicine and Health Sciences Researches Congress (UTSAK), Ankara, Türkiye, 26 - 27 Ağustos 2023, ss.1352-1361, (Tam Metin Bildiri)
Malign hyperthermia (MH) is a syndrome characterized by a series of hypermetabolic events that occur
after the administration of inhalation anesthetics such as halothane, isoflurane, sevoflurane, and/or depolarizing
muscle relaxants in susceptible individuals. The cause of this condition, which has been reported in both humans
and animals, has been determined to be an autosomal skeletal muscle disease. This syndrome, with its initial
symptom being hypercapnia, begins with symptoms such as tachycardia, tachypnea, cyanosis, muscle rigidity, and
arrhythmia. With a severe course, it can result in complete disruption of metabolic activities and lead to death.
Due to the diversity of clinical symptoms, treatment should be carried out systematically. The inability to make a
pre-anesthesia diagnosis through routine tests, insufficient monitoring, delayed detection and intervention, and
the lack of necessary drugs, equipment, and knowledge for MH increase the mortality rate. It has been reported
that in modern times, the mortality rate has decreased with the awareness of veterinarians in this field and the
increasing use of dantrolene sodium, the specific antidote for the syndrome. However, due to the relatively low
incidence of MH and the inability to obtain high-cost monitoring equipment and dantrolene sodium in certain
regions, mortality rates still remain high. In this review, different cases of MH are evaluated from past to present,
with a focus on the most commonly encountered problems and overlooked points during this process. Furthermore,
by systematically presenting how the syndrome should be managed in cases where dantrolene can or cannot be
obtained, and by providing alternative treatment methods, the aim is to increase the survival rate from the lifethreatening complication of MH through early and accurate intervention.